Clinical Trials List
2024-09-01 - 2032-12-31
Phase III
Recruiting5
ICD-10C19
Malignant neoplasm of rectosigmoid junction
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9154.0
Malignant neoplasm of rectosigmoid junction
-
-
Trial Applicant
Johnson & Johnson
-
Sponsor
-
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/05/16
Investigators and Locations
Co-Principal Investigator
- Peng-Chan Lin 無
- Po-Wen Lin 無
- 黃盈慈 無
- 黃怡璇 無
- 黃怡菁 無
- 鍾秉軒 無
- Shang-Hung Chen 無
- Jui-Hung Tsai 無
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Wen-Chi Chou 無
- Jen-Shi Chen 無
- 賴盈傑 無
- 呂嘉偉 無
- Yung-Chia Kao 無
- Tsai-Sheng Yang 無
- Mengting Peng 無
- 余紹銘 無
- 張境夫 無
- 黃振洋 無
- Ming-Mo Hou 無
- 黃文冠 無
- Chia-Hsun Hsieh 無
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Study Contacts
- -
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
Exclusion Criteria
The Estimated Number of Participants
-
Taiwan
50 participants
-
Global
1000 participants
